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Baltimore declares O'Toole mistaken 
Dr Margot O'Toole's comment on the OSI draft report reproduced in Nature two weeks ago, has drawn the following 
reply from Dr David Baltimore, one of the authors of an article alleged to include fraudulent data. 
DocroR Margot O'Toole's recent comments 
on the draft report of the National Institutes 
of Health Office of Scientific Integrity 
(Nature 351, 180; 16 May 1991) create a 
misleading impression and therefore require 
a response. The issues she raises have all pre-
viously been answered, often several times, 
but because many are not familiar with the 
details, I feel that it is necessary to demon-
strate publicly that her charges lack sub-
stance. 
I have already submitted comments on the 
draft report of the investigation conducted 
by the OSI into the controversy over the Cell 
paper. In them, I acknowledged certain 
errors of judgement on my part, commended 
Dr Margot O'Toole for her courage and 
insight and volunteered to participate in the 
continuing dialogue with Congress and other 
government bodies responsible for the over-
sight of scientific research supported by pub-
lic funds. 
The OSI report contained no allegations 
or findings that I participated in any falsifica-
tion or fabrication of data, but its criticisms 
of me focused upon my defence of my co-
author, Dr Thereza Imanishi-Kari, particu-
larly at the May 1989 hearings before the 
congressional subcommittee. My comments 
explained that my defence of her grew out of 
the trust and respect I had for my collabora-
tor's demonstrated abilities as a scientist, my 
understanding that the molecular analysis 
conducted in my laboratory validated Dr 
lmanishi-Kari's conclusions and my belief in 
the efficacy of the peer review process. 
Since then, Dr O'Toole has commented 
publicly about my statement, and released a 
lengthy response to the OSI draft report that 
enumerates the charges she is now making. 
These are the remarks published in Nature. 
Dr O'Toole's response, unlike the OSI 
draft report, contains allegations that I was 
aware before the completion of the OSI 
report that statements in the Cell paper were 
untruthful, that I was remiss in submitting a 
letter of correction to Cell citing the unpub-
lished data by Dr lmanishi-Kari which Dr 
O'Toole states were false and that I have 
publicly attacked Dr O'Toole's competence 
and motives. For those reasons, I believe it is 
incumbent upon me to clarify these matters. 
Dr O'Toole's response contains new char-
ges that are different from her original con-
structive questions on matters of science, and 
also includes certain overstatements and 
errors. Any assessment of her claims must 
take into consideration a number of facts she 
has not mentioned, and I have therefore pro-
vided the information that follows. 
• The importance of the notebooks dis-
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discovered by Dr O'Toole. Dr O'Toole 
begins her recitation of the history of the 
controversy by stating that in May 1986, she 
came across laboratory records "for experi-
ments on which the central claim was based" 
and that it was "obvious" from those records 
that the experiment had not yielded the pub-
lished results. She goes on to state that this 
flaw "remains evident", and that Herman 
Eisen of Massachusetts Institute of Technol-
ogy (MIT) said to her that the evidence 
"appeared to indicate fraud". 
The 17 pages of data Dr O'Toole copied 
were taken not from the notebooks of Dr 
lmanishi-Kari, but from those of Dr lmani-
shi-Kari's postdoctoral fellow, Moema Reis. 
Dr Reis's data have not been challenged. The 
The article based on Dr Margot O'Toole's 
comment on the draft report by the NIH 
Office of Scientific Integrity (Nature 
351, 180; 16 May 1991) has under-
standably provoked controversy. At 
issue is the authenticity of the data on 
which an article published in 1986 is 
based (Weaver, D. eta/. Cell). This sym-
posium of documents includes replies to 
O'Toole from two of those whom she 
criticized - Dr David Baltimore (presi-
dent of the Rockefeller University) and 
Dr HermanN. Eisen (MIT)- as well as a 
much-abridged version of Dr Thereza 
lmanishi-Kari's comment on the 051 
draft report, published in March (Nature 
350, 263; 28 March 1991). Baltimore's 
own response to the same report 
appeared on 9 May (Nature 351, 94; 
1991). Others who have signalled their 
wish to join this discussion will be 
accommodated as space permits. 
major element of the 17 pages that appeared 
to contradict the study were data supposedly 
derived from a control mouse. These dif-
fered from the published data on control 
mice. 
It was discovered quite quickly, at the first 
meetings in May 1986 when Dr O'Toole 
raised her challenge, that the mouse in the 17 
pages had been mistyped- it was not a con-
trol mouse and was in fact, transgenic. Data 
on truly normal mice were generated, and it 
was those findings that were used in the 
paper. 
Although Dr O'Toole has acknowledged 
these facts in the past, she continues to 
charge that the 17 pages contradict the pub-
lished paper, while neglecting to mention 
that the pages have proved to be irrelevant. 
By citing Dr Eisen's comment, she leaves the 
impression that the data she found are evi-
dence of fraud. This issue has been defini-
tively resolved and therefore, Dr O'Toole's 
statement that the discrepancy "remains evi-
dent" is incorrect, and her reference to the 
data she discovered and Dr Eisen's reaction 
to it is misleading. 
• Dr O'Toole's challenge to Figure 1. Dr 
O'Toole states that the paper's Figure 1 is 
"not truthful". She repeats at several points 
that experiments "central to the paper" had 
been performed, but did "not yield the pub-
lished results". Dr O'Toole does not identify 
the experiments involved, but she has made 
such statements before when discussing the 
issues surrounding the reagent BET-1. Her 
original challenge focused largely on her 
belief that BET -1, a reagent used to distin-
guish between the antibodies that were the 
object of the study, and described in Figure 
1, did not work. The airing of her views in 
1986led quickly to a realization that the spe-
cificity of BET -1 had been somewhat over-
stated in the paper. 
Dr O'Toole repeats the allegations 
although this mistake was subject of a letter 
of correction to Cell in October 1988, two 
and a half years ago. This overstatement has 
been deemed a mistake by the Tufts, MIT 
and NIH reviewers and not the product of 
fraud. 
Dr O'Toole persists in challenging Figure 
1. Every academic committee or govern-
ment agency that has reviewed the matter has 
rejected her contention that BET-1 does not 
work at all. Indeed, the January 1989 report 
of the first NIH panel pointed out that data 
showing the effectiveness of BET -1 could be 
found in Dr O'Toole's own notebooks. 
• The subclone data submitted with the 
May 1989 letter of correction to Cell. 
One of Dr O'Toole's most serious charges is 
that I published information as part of the 
1989letter of correction to Cell that I knew 
was false. Dr O'Toole states that the experi-
ments on subcloning of the hybridoma wells 
in Table 2, described in the letter, were not in 
fact performed. Although she does not 
expressly state that I knew the data to be fab-
ricated, her complaint that I submitted the 
letter to Cell, even after she told NIH in 
November 1988 that what have become 
known as the "June subcloning" experi-
ments had not been performed, leaves the 
impression that I made a knowing misrep-
resentation. This conclusion is untrue. 
First, I wish to state categorically that I 
have not throughout the history of this mat-
ter made a statement that was known to me 
to be untrue, or which l even suspected was 
untrue. In addition, I have never heard from 
Dr lmanishi-Kari that she did not perform 
any of the experiments described in the Cell 
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paper, or in the various published correc-
tions. The fact that, in 1987, I called for a full 
review of the matter by NIH indicates that, in 
my mind, we had nothing to hide. 
In November 1988, the first NIH panel to 
study the matter issued its draft report. Dr 
O'Toole responded and charged for the first 
time that the panel was drawing its conclu-
sions from experiments which she said Dr 
Imanishi-Kari told her had not been done. 
She stated that Dr Imanishi-Kari told her 
during the course of the review by the Tufts 
ad hoc committee that no subcloning 
analysis of the Table 2 hybridomas had been 
performed and Dr O'Toole denied that 
subcloning data had been reviewed during 
those meetings. As I was not present during 
the Tufts meetings, and I had never heard Dr 
Imanishi-Kari make such a statement, I had 
no personal knowledge with which to verify 
or refute Dr O'Toole's remarks. 
In December 1988, NIH solicited more 
information from Dr Imanishi-Kari and 
from Dr Henry Wortis, Dr Brigitte Huber of 
Tufts and Dr Robert Woodland of the 
University of Massachusetts, who had con-
ducted the review for Tufts. All confirmed 
that in May 1986, they reviewed the data in 
support of Table 2, that the data supported 
Table 2 and its conclusions, and that the sub-
cloning analysis was discussed with Dr 
lmanishi-Kari. The reviewers met with Dr 
lmanishi-Kari on 16 May 1986, when Dr 
O'Toole was not present. 
The NIH panel stated in its final report 
that it carefully reviewed Dr O'Toole's let-
ters, but found that no modification to its 
report was necessary. I believe, then, that my 
acceptance of the data as authentic at the 
time was justified. No forensic analysis had 
as yet been performed. Moreover, the OSI 
draft report states that Dr Reis told the inves-
tigators that she participated in performing 
the experiments. 
• The isotyping experiments. Dr 
O'Toole states that Dr Imanishi-Kari told 
me and the others assembled for the meeting 
with Herman Eisen of MIT in June 1986 
that, in preparing Table 2 for publication, 
"she relied completely on her prior expecta-
tion of what the results would be", and she 
states that Dr Imanishi-Kari admitted in my 
presence "that a large series of the published 
experiments had not even been performed." 
Dr O'Toole's failure to specify which 
experiments she means complicates any 
effort to respond, but the questions concern-
ing the isotyping experiments on the Table 2 
hybridomas were answered long ago. The 
experiments were in fact done, but -
unknown to me at the time - the exact 
materials used were misidentified in the 
paper. The point was dealt with in the letter 
of correction to Cell in November 1988, and 
it is unclear to me why this issue would be 
raised now. 
• The impact of the Secret Service 
briefing in 1989. Dr O'Toole faults me for 
defending Dr Imanishi-Kari in my May 1989 
testimony before Congress, even though the 
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Secret Service and members of the staff of 
the congressional subcommittee had met me 
before the hearings to review the forensic 
findings. At that meeting, the Secret Ser-
vice's work was still in progress; some of the 
irregularities the agents had uncovered in the 
notebooks were described to me in a very 
fragmentary and unsystematic fashion, with-
out the aid of demonstrative charts or formal 
reports. The briefing did not touch on the 
evidence stressed in the recent OSI draft 
report - the analysis of paper used in the 
printer attached to the gamma counter. 
The types of difficulties generally 
described to me - for instance, the obvious 
changing or adding of dates - seemed at the 
time to be as consistent with Dr Imanishi-
Kari's known reorganization of her original 
materials as with any effort to commit fraud. 
When I met the Secret Service, I discussed at 
length how the notebooks had come to be 
put together. 
For the reasons cited above, and because I 
had a high regard for Dr lmanishi-Kari, I did 
not abandon my faith in her at the time. In 
hindsight, as I have explained in my com-
ments to OSI, it would have been prudent to 
step back and review the evidence before 
commenting further; my failure to do so 
demonstrates only my high degree of trust in 
a fellow scientist, and not any intent to 
deflect or obstruct an investigation. 
Dr O'Toole expresses her view that I was 
not forthcoming with Congress because I did 
not explain that the pages of original data for 
the paper were organized into book form 
before being submitted to NIH in July 1988. 
I have made no secret of the fact that, when I 
first saw the records, they were not in books, 
but were a mixture of notebooks, loose paper 
and data sheets. Dr Imanishi-Kari acted on 
the advice of a lawyer and against my advice 
in pulling them together into an organized 
form to facilitate their review by scientists of 
NIH. I have stated this on numerous occa-
sions over the years, as well as in interviews 
with OSI and the Secret Service. 
• The 1991 retraction. When summariz-
ing the history of the matter, Dr O'Toole 
refers to the issuing of the OSI draft report 
and states: "Only then, five years after he 
learned of the problems, did Dr Baltimore 
retract the paper." This sweeping statement 
conveys the impression that "the problems" 
contained in the OSI report were known to 
me for five years, but the factual circumstan-
ces are quite different. 
The serious allegations contained in the 
OSI report first became known to me in 
March this year, when the report was sent to 
me for comment. Five years ago, "the prob-
lems" identified by Dr O'Toole were of an 
entirely different nature. Her written memo-
randum to Dr Eisen of MIT in June 1986 
specified the problems as she saw them. 
Then, Dr O'Toole expressed her view that 
the data did not support the paper's conclu-
sion, and she proposed alternative explana-
tions for the observed phenomena. In 1986, 
Dr O'Toole challenged the specificity of 
BET -1 and claimed that Table 2 understated 
the frequency of certain findings with respect 
to normal mice. 
She challenged the paper's finding that it 
was the endogenous gene, and not the trans-
gene, that was being expressed when idio-
type-positive antibodies - that is, those 
characteristic of the transgene - were found 
in hybridomas from transgenic mice. Her 
argument was that the assays used were 
inadequate and insufficiently sensitive to 
detect the presence of the trans gene. In other 
words, she questioned the accuracy of the 
paper's conclusion on matters of science. 
In 1986 and 1987, Dr O'Toole was 
emphatic that she was alleging error, and not 
charging fraud. When she appeared before 
Congress in April 1988, she continued to 
stress that she was concerned only about 
error and basic scientific principles. Her alle-
gations about the fabrication ofthe June sub-
cloning data were not raised until late 
November 1988. Thus, her suggestion that I 
ignored charges of the seriousness of those 
contained in the OSI draft report for five 
years is not accurate. 
Dr O'Toole also states that I "consistently 
and falsely" maintained that her objections 
were no more than alternative interpreta-
tions of valid data. The Tufts committee, Dr 
Eisen of MIT, and NIH reached precisely 
this conclusion and Dr O'Toole herself 
insisted in 1986, 1987 and 1988 that her only 
concern was for the validity of the science. 
• Compliance with NIH recommenda· 
tions. Dr O'Toole states that the authors did 
not comply with the recommendation of the 
NIH panel contained in its January 1989 
report. This statement is incorrect. We com-
plied with all of the recommendations and 
the director of NIH accepted our response as 
appropriate. 
• The meeting of Dr O'Toole, the auth· 
ors and Dr Eisen of MIT. Dr O'Toole pro-
vides a detailed description of the June 1986 
meeting with Dr Eisen of MIT. Her account 
is couched in terms that incorrectly suggest 
that we were told then of a series of misrep-
resentations and that at the time I advised 
against a further public airing of her views. 
First, Dr O'Toole states that I "acknow-
ledged" at the time that the published results 
could not be based upon the data she brought 
to the meeting, that is, the 17 pages from Dr 
Reis's notebook described above. The 17 
pages, as I have explained, had already been 
determined to be irrelevant. 
Second, Dr O'Toole states that Dr 
Imanishi-Kari "admitted that a large series of 
the published experiments had not even been 
performed". It is simply not true that any 
large series of experiments had not been per-
formed. Perhaps this overly broad reference 
is to the fact that the Table 2 idiotype type 
experiments were not done on the particular 
hybridomas indicated, but were performed 
on other hybridomas. That has already been 
the subject of a published correction. 
If Dr lmanishi-Kari had stated at the meet-
ing that she did not perform any of the 
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experiments, I would have immediately 
questioned the veracity of the paper. My 
remembrance that she made no such state-
ment is supported by the sworn testimony of 
Dr Eisen before Congress that the question 
of tests not being performed never came up 
at the meeting. 
Finally, Dr O'Toole states that I told her I 
would personally oppose any effort she 
might make to get the paper corrected. I do 
recall Dr O'Toole discussing, just as the 
meeting was ending, the prospect of her 
sending a letter to Cell specifying her criti-
cisms. I did say, I believe, that the authors 
would then probably respond to her letter. I 
believe that such a response would have been 
appropriate in normal scientific disagree-
ments. 
Dr O'Toole's description ofthis exchange 
differs significantly from the account she 
submitted to Congress in April1988 as part 
of her written chronology. There she states 
that I proposed that she could write to the 
journal and noted that I would respond. She 
goes on to say that she then "stated that [she] 
consider[ ed] [her] responsibilities dis-
charged and intended to drop the matter." 
Dr O'Toole's own previous version of the 
events contradicts the theory she is advanc-
ing now: that she wished to pursue the matter 
further in the journal, but that I intimidated 
her from doing so. 
• My views on fraud in science. Dr 
O'Toole purports to describe my views and 
incorrectly states that I maintain that "false 
claims do not have to be corrected because 
other investigators will stumble on error and 
clear things up eventually." This is a gross 
parody of my stated belief that the scientific 
process is the best means to test the scientific 
validity of published claims. As I have 
repeated in my articles on the subject, my 
congressional testimony and, most recently, 
in my response to the OSI draft report, con-
sciously false claims, or fraud, by a scientist 
can never be excused or condoned. 
• Dr O'Toole's claim that she has been 
personally attacked. Dr O'Toole states 
that throughout the history of this matter, 
there have been "attacks on [her] com-
petence and motives". She also states that 
she was subjected to "five years of slander 
and libel from Drs Baltimore, Eisen and 
Imanishi-Kari." Dr O'Toole makes this 
accusation, yet she cites not one example of 
any comment by me in which I publicly dis-
paraged her or her ideas. 
At the June 1986 meeting, I stated that I 
considered Dr O'Toole's criticisms to be 
imaginative and thoughtful. When Dr Eisen 
wrote a report about the meeting, he 
remarked, "I do not think that I or anyone 
present at the meeting felt that Margot 
O'Toole's disagreements were frivolous." 
None of my written statements or testimony 
about the matter raised any question about 
Dr O'Toole's abilities as a scientist or her 
motives. I told the congressional subcommit-
tee that Dr O'Toole's criticisms "were a 
rational and appropriate part of the scientific 
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process". My comments to OSI stated that 
her analyses were insightful, her expressions 
of concern were proper and appropriate and 
her motives were pure. 
While Dr O'Toole has now directly 
attacked my honesty and integrity, none of 
my previous remarks nor any of the remarks 
in this statement were intended to criticize 
her personally, impugn her abilities as a 
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scientist or question her motives. Rather, I 
have made this statement in the hope that 
any assessment of the validity of her 
comments will be a measured one, based 
upon a consideration of all of the facts and the 
entire record of this controversy, includ-
ing Dr O'Toole's own previous statements 
on the matter. 
David Baltimore 
Origins of MIT inquiry 
Dr Herman N Eisen, who conducted the inquiry at MIT in 1986, denies 
Dr O'Toole's account of its proceedings, and other charges. 
DocroR Margot O'Toole makes a series of 
assertions that effectively charge me and 
many others with dishonest and irrespon-
sible behaviour. These assertions cannot go 
unchallenged. In what follows, I address sev-
eral of her more extreme statements, those 
that from personal knowledge I know to be 
inaccurate or grossly to misrepresent the true 
events. 
It is important to clarify the circumstances 
surrounding the initial inquiry at MIT, now 
characterized by Dr O'Toole as a "cover-
up". I met and spoke to Dr O'Toole on three 
occasions, all in the spring of 1986. First, she 
told me in March or April of experimental 
and personal difficulties she was experien-
cing in Dr Imanishi-Kari's laboratory. Sec-
ond, on 30 or 31 May, she visited me at 
Woods Hole to describe her concerns about 
the validity of the Weaver eta/. paper. Third, 
on 16 June 1986 she and I met the paper's 
authors (Baltimore, Imanishi-Kari and 
Weaver) to consider the memorandum she 
had prepared at my request. 
In that memorandum (dated 6 June), Dr 
O'Toole elaborated clearly and at length on 
what she saw as four principal sources of 
error in the paper. However, it contains no 
suggestion that reported results were based 
on nonexistent or fraudulent data. I have 
read that memo many times since, searching 
for indications of the fraud that Dr O'Toole 
later proclaimed so vigorously but I have 
found none. 
I have, therefore, long been puzzled by Dr 
O'Toole's turn-around in asserting- begin-
ning, I think, two years later - that fraud was 
evident at the very start. Recently, however, I 
have come upon a hint of an explanation: in 
testimony before the Dingell subcommittee 
on 12 April1988, Dr O'Toole stated that her 
memo of 6 June 1986 had been edited before 
being submitted to me to remove "any lan-
guage that might possibly imply that she was 
alleging any misconduct". 
She presumably took this action to avoid 
making an allegation of fraud without sub-
stantial evidence, as such a charge might 
expose her to legal action. While her trepida-
tion is understandable, the result was a 
carefully manicured memorandum that 
contained no hint of fraud. In consequence, I 
was presented with a document that, except 
for its intensity and length, had all the hall-
marks of a typical scientific dispute, the kind 
editors see repeatedly between authors and 
an intelligent, intensely engaged and critical 
reviewer of a manuscript. 
Thus it is not inappropriate to ask: who 
misled whom? It is ironic and sad that, 
instead of recognizing that she bears some 
responsibility for creating a misleading situ-
ation, Dr O'Toole now characterizes the 
initial inquiry at MIT as a "cover-up". Given 
her choice of words, I also find it remarkable 
that those of us who were involved in the 
inquiry are accused of slander and libel. 
I now consider the particular statements of 
Dr O'Toole's that are especially serious and 
that I find to be completely at odds with the 
events as I know them. 
• Dr O'Toole asserts that, at the 16 June 
1986 meeting, "Dr Imanishi-Kari again 
admitted that a large series of the published 
experiments had not even been performed 
and that some which were performed had not 
yielded the claimed results." I deny that such 
a statement, amounting to a clear admission 
of fraud, was made at that meeting in my 
presence - and I was present throughout. 
Had such a striking confession been made at 
the time, it is difficult to understand why Dr 
O'Toole failed to mention it in her testimony 
before the Dingell subcommittee in 1988. 
• Dr O'Toole asserts repeatedly that the 17 
pages she obtained from Dr Reis's notebook 
provided obvious evidence of problems with 
the paper. Her allegation grossly oversim-
plifies the complexity of the material. Walter 
Stewart, testifying two years later before the 
Dingell subcommittee, stated that the lan-
guage in these pages was in "Portuguese or 
some other language" and that the pages 
were "extremely confusing because they 
consisted mainly of numbers". Earlier, I had 
asked him how long it has taken him to make 
sense of the 17 pages. He replied in one 
word: "weeks". 
At the time, however, the presence in 
those pages of some data that did not agree 
with published material did not seem 
unusual. Notebooks commonly contain 
much imperfect data accumulated on the 
way to obtaining definitive results for publi-
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